Cell Therapeutics (CTIC -0.7%) says the Gynecologic Oncology Group has informed it that an...

|About: CTI BioPharma Corp. (CTIC)|By:, SA News Editor

Cell Therapeutics (CTIC -0.7%) says the Gynecologic Oncology Group has informed it that an independent Data Safety Monitoring Board has recommended the continuation of Phase 3 clinical trials of Opaxiotm, a therapy for ovarian cancer, with no changes following a planned interim survival analysis.